Trends in Government-Subsidised Menopausal Hormone Therapy Dispensing in Australia Between 2014 and 2023.

Hindun Wilda Risni, Li Wei, Martha Hickey, Luke Grzeskowiak, Jenni Ilomäki, Ruth Brauer

Abstract read

In one paragraph

Article in The Australian & New Zealand journal of obstetrics & gynaecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hindun Wilda RisniResearch Department of Practice and Policy, University College London School of Pharmacy, London, UK.ORCID https://orcid.org/0000-0002-8000-6992

Li WeiResearch Department of Practice and Policy, University College London School of Pharmacy, London, UK.

Martha HickeyThe University of Melbourne, Parkville, Victoria, Australia.

Luke GrzeskowiakCollege of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University, Bedford Park, South Australia, Australia.ORCID https://orcid.org/0000-0001-8554-4696

Jenni IlomäkiCentre for Medicine Use and Safety, Monash University, Melbourne, Victoria, Australia.

Ruth BrauerResearch Department of Practice and Policy, University College London School of Pharmacy, London, UK.ORCID https://orcid.org/0000-0001-8934-347X

Funding

Indonesia Endowment Fund for Education 202307223267940Pharmalliance ECR grant

6 · The paper itself

Abstract

Menopausal hormone therapy (MHT) is a mainstay treatment for menopausal symptoms. While international studies report rising MHT use, trends in Australia remain unclear. Using a 10% random sample of Pharmaceutical Benefits Scheme (PBS) data from 2014 to 2023, we analysed the prevalence of MHT dispensing among women aged 45-64. Overall prevalence of MHT dispensing remained stable (relative annual change: 0.42%, 95% CI -0.50 to 1.35). Use of transdermal and intrauterine device (IUD) MHT increased (5.89%, 95% CI 3.88-7.91 and 10.22%, 95% CI 9.48-10.95, respectively), and vaginal MHT decreased (-1.47%, 95% CI -2.30 to -0.63), while oral MHT appeared stable (0.66%, 95% CI -0.04 to 1.36). This study offers a clearer understanding of how MHT use in Australia has changed over the last decade.

Indexed as

Estrogen Replacement TherapyMenopauseAdministration, CutaneousAustraliaFemaleHumansIntrauterine DevicesMiddle AgedAustraliadispensingmenopausal hormone therapytrendwomen

Identifiers

PMID42032843

DOI10.1111/ajo.70135

PMCPMC13109606

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.